The human proteome is rich with protein kinases, and this richness has made the kinase of crucial importance in initiating and maintaining cell behavior. Elucidating cell signaling networks and manipulating their components to understand and alter behavior require well designed inhibitors. These inhibitors are needed in culture to cause and study network perturbations, and the same compounds can be used as drugs to treat disease. Understanding the structural biology of protein kinases in detail, including their commonalities, differences and modes of substrate interaction, is necessary for designing high quality inhibitors that will be of true use for cell biology and disease therapy. To this end, we here report on a structural analysis of all available active-conformation protein kinases, discussing residue conservation, the novel features of such conservation, unique properties of atypical kinases and variability in the context of substrate binding. We also demonstrate how this information can be used for structure prediction. Our findings will be of use not only in understanding protein kinase function and evolution, but they highlight the flaws inherent in kinase drug design as commonly practiced and dictate an appropriate strategy for the sophisticated design of specific inhibitors for use in the laboratory and disease therapy.
References
[1]
Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298: 1912–1934.
[2]
Yamaguchi H, Matsushita M, Nairn AC, Kuriyan J (2001) Crystal structure of the atypical protein kinase domain of a TRP channel with phosphotransferase activity. Mol Cell 7: 1047–1057.
[3]
LaRonde-LeBlanc N, Wlodawer A (2005) A family portrait of the RIO kinases. J Biol Chem 280: 37297–37300.
[4]
Dedhar S, Williams B, Hannigan G (1999) Integrin-linked kinase (ILK): a regulator of integrin and growth-factor signaling. Trends Cell Biol 9: 319–323.
[5]
Ubersax JA, Woodbury EL, Quang PN, Paraz M, Blethrow JD, et al. (2003) Targets of the cyclin-dependent kinase Cdk1. Nature 425: 859–864.
[6]
Ptacek J, Devgan G, Michaud G, Zhu H, Zhu X, et al. (2005) Global analysis of protein phosphorylation in yeast. Nature 438: 679–684.
[7]
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, et al. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182.
[8]
Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340: 1330–1340.
[9]
Hommes D, van den Blink B, Plasse T, Bartelsman J, Xu C, et al. (2002) Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 122: 7–14.
[10]
Ono-Saito N, Niki I, Hidaka H (1999) H-series protein kinase inhibitors and potential clinical applications. Pharmacol Ther 82: 123–131.
[11]
Sebolt-Leopold JS, English JM (2006) Mechanisms of drug inhibition of signaling molecules. Nature 441: 457–462.
[12]
Fabian MA, r d Biggs WH, Treiber DK, Atteridge CE, Azimioara MD, et al. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23: 329–336.
[13]
Rohl CA, Strauss CE, Misura KM, Baker D (2004) Protein structure prediction using Rosetta. Methods Enzymol 383: 66–93.
[14]
LaRonde-LeBlanc N, Wlodawer A (2004) Crystal structure of A. fulgidus Rio2 defines a new family of serine protein kinases. Structure 12: 1585–1594.
[15]
Grishin NV (2001) Fold change in evolution of protein structures. J Struct Biol 134: 167–185.
[16]
Todd AE, Orengo CA, Thornton JM (2002) Plasticity of enzyme active sites. Trends Biochem Sci 27: 419–426.
[17]
Carrera AC, Alexandrov K, Roberts TM (1993) The conserved lysine of the catalytic domain of protein kinases is actively involved in the phosphotransfer reaction and not required for anchoring ATP. Proc Natl Acad Sci U S A 90: 442–446.
[18]
Robinson MJ, Harkins PC, Zhang J, Baer R, Haycock JW, et al. (1996) Mutation of position 52 in ERK2 creates a nonproductive binding mode for adenosine 5′-triphosphate. Biochemistry 35: 5641–5646.
[19]
Iyer GH, Garrod S, r Woods VL J, Taylor SS (2005) Catalytic independent functions of a protein kinase as revealed by a kinase-dead mutant: study of the Lys72His mutant of cAMP-dependent kinase. J Mol Biol 351: 1110–1122.
[20]
Drennan D, Ryazanov AG (2004) Alpha-kinases: analysis of the family and comparison with conventional protein kinases. Prog Biophys Mol Biol 85: 1–32.
[21]
Xu B, English JM, Wilsbacher JL, Stippec S, Goldsmith EJ, et al. (2000) WNK1, a novel mammalian serine/threonine protein kinase lacking the catalytic lysine in subdomain II. J Biol Chem 275: 16795–16801.
[22]
Min X, Lee BH, Cobb MH, Goldsmith EJ (2004) Crystal structure of the kinase domain of WNK1, a kinase that causes a hereditary form of hypertension. Structure 12: 1303–1311.
[23]
Zheng J, Trafny EA, Knighton DR, Xuong NH, Taylor SS, et al. (1993) 2.2 ？ refined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MnATP and a peptide inhibitor. Acta Crystallogr D Biol Crystallogr 49: 362–365.
[24]
Lei M, Lu W, Meng W, Parrini MC, Eck MJ, et al. (2000) Structure of PAK1 in an autoinhibited conformation reveals a multistage activation switch. Cell 102: 387–397.
[25]
Yang J, Cron P, Good VM, Thompson V, Hemmings BA, et al. (2002) Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat Struct Biol 9: 940–944.
[26]
Huang J, Tu Z, Lee FS (2003) Mutations in protein kinase subdomain X differentially affect MEKK2 and MEKK1 activity. Biochem Biophys Res Commun 303: 532–540.
[27]
Tu Z, Mooney SM, Lee FS (2003) A subdomain of MEKK1 that is critical for binding to MKK4. Cell Signal 15: 65–77.
[28]
Felberg J, Lefebvre DC, Lam M, Wang Y, Ng DH, et al. (2004) Subdomain X of the kinase domain of Lck binds CD45 and facilitates dephosphorylation. J Biol Chem 279: 3455–3462.
[29]
Kim C, Xuong NH, Taylor SS (2005) Crystal structure of a complex between the catalytic and regulatory (RIalpha) subunits of PKA. Science 307: 690–696.
[30]
Das R, Qian B, Raman S, Vernon R, Thompson J, et al. Prediction of the structures of CASP7 targets using extensive all-atom refinement with Rosetta@home. Proteins; In press.
[31]
Thompson JD, Higgins DG, Gibson TJ (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22: 4673–4680.
[32]
Biondi RM, Komander D, Thomas CC, Lizcano JM, Deak M, et al. (2002) High resolution crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site. EMBO J 21: 4219–4228.
[33]
Hawkins J, Zheng S, Frantz B, LoGrasso P (2000) p38 map kinase substrate specificity differs greatly for protein and peptide substrates. Arch Biochem Biophys 382: 310–313.
[34]
Biondi RM, Nebreda AR (2003) Signaling specificity of Ser/Thr protein kinases through docking-site-mediated interactions. Biochem J 372: 1–13.
[35]
Liu Y, Bishop A, Witucki L, Kraybill B, Shimizu E, et al. (1999) Structural basis for selective inhibition of Src family kinases by PP1. Chem Biol 6: 671–678.
[36]
Blencke S, Zech B, Engkvist O, Greff Z, Orfi L, et al. (2004) Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem Biol 11: 691–701.
[37]
Bogoyevitch MA, Barr RK, Ketterman AJ (2005) Peptide inhibitors of protein kinases-discovery, characterization and use. Biochim Biophys Acta 1754: 79–99.
[38]
Perea SE, Reyes O, Puchades Y, Mendoza O, Vispo NS, et al. (2004) Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2). Cancer Res 64: 7127–7129.
[39]
Shah K, Shokat KM (2003) A chemical genetic approach for the identification of direct substrates of protein kinases. Methods Mol Biol 233: 253–271.
[40]
Goodall C (1991) Procrustes methods in the statistical analysis of shape. J R Statist Soc B 53: 285–339.
[41]
Dryden IL, Mardia KV (1998) Statistical shape analysis. Chichester: Wiley.
[42]
Claude J, Pritchard P, Tong H, Paradis E, Auffray JC (2004) Ecological correlates and evolutionary divergence in the skull of turtles: a geometric morphometric assessment. Syst Biol 53: 933–948.
[43]
Kent JT (1992) New directions in shape analysis. In: Mardia KV, editor. The art of statistical science. Chichester: Wiley. pp. 115–127.
[44]
Gutteridge A, Thornton JM (2005) Understanding nature's catalytic toolkit. Trends Biochem Sci 30: 622–629.
[45]
Knighton DR, Zheng JH, Eyck LFT, Ashford VA, Xuong NH, et al. (1991) Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 253: 407–414.
[46]
Lougheed JC, Chen RH, Mak P, Stout TJ (2004) Crystal structures of the phosphorylated and unphosphorylated kinase domains of the Cdc42-associated tyrosine kinase ACK1. J Biol Chem 279: 44039–44045.
[47]
Russo AA, Jeffrey PD, Pavletich NP (1996) Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat Struct Biol 3: 696–700.
[48]
Xu RM, Carmel G, Sweet RM, Kuret J, Cheng X (1995) Crystal structure of casein kinase-1, a phosphate-directed protein kinase. EMBO J 14: 1015–1023.
[49]
Yde CW, Ermakova I, Issinger OG, Niefind K (2005) Inclining the purine base binding plane in protein kinase CK2 by exchanging the flanking side-chains generates a preference for ATP as a cosubstrate. J Mol Biol 347: 399–414.
[50]
Tereshko V, Teplova M, Brunzelle J, Watterson DM, Egli M (2001) Crystal structures of the catalytic domain of human protein kinase associated with apoptosis and tumor suppression. Nat Struct Biol 8: 899–907.
[51]
Hubbard SR (1997) Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J 16: 5572–5581.
[52]
Bellon S, Fitzgibbon MJ, Fox T, Hsiao HM, Wilson KP (1999) The structure of phosphorylated p38gamma is monomeric and reveals a conserved activation-loop conformation. Structure 7: 1057–1065.
[53]
Owen DJ, Noble ME, Garman EF, Papageorgiou AC, Johnson LN (1995) Two structures of the catalytic domain of phosphorylase kinase: an active protein kinase complexed with substrate analogue and product. Structure 3: 467–482.
[54]
Qian KC, Wang L, Hickey ER, Studts J, Barringer K, et al. (2005) Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase. J Biol Chem 280: 6130–6137.
[55]
Young TA, Delagoutte B, Endrizzi JA, Falick AM, Alber T (2003) Structure of Mycobacterium tuberculosis PknB supports a universal activation mechanism for Ser/Thr protein kinases. Nat Struct Biol 10: 168–174.
[56]
LaRonde-LeBlanc N, Guszczynski T, Copeland T, Wlodawer A (2005) Autophosphorylation of Archaeoglobus fulgidus Rio2 and crystal structures of its nucleotide-metal ion complexes. FEBS J 272: 2800–2810.
[57]
Nolen B, Ngo J, Chakrabarti S, Vu D, Adams JA, et al. (2003) Nucleotide-induced conformational changes in the Saccharomyces cerevisiae SR protein kinase, Sky1p, revealed by X-ray crystallography. Biochemistry 42: 9575–9585.
[58]
Zhou T, Raman M, Gao Y, Earnest S, Chen Z, et al. (2004) Crystal structure of the TAO2 kinase domain: activation and specificity of a Ste20p MAP3K. Structure 12: 1891–1900.
[59]
Nolen B, Yun CY, Wong CF, McCammon JA, Fu XD, et al. (2001) The structure of Sky1p reveals a novel mechanism for constitutive activity. Nat Struct Biol 8: 176–183.
